Protara Therapeutics, Inc. (NASDAQ:TARA - Free Report) - Research analysts at Cantor Fitzgerald decreased their FY2025 earnings per share (EPS) estimates for shares of Protara Therapeutics in a note issued to investors on Thursday, March 20th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will earn ($1.71) per share for the year, down from their previous forecast of ($1.62). Cantor Fitzgerald has a "Overweight" rating on the stock. The consensus estimate for Protara Therapeutics' current full-year earnings is ($3.32) per share.
Protara Therapeutics (NASDAQ:TARA - Get Free Report) last released its quarterly earnings data on Wednesday, March 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.57) by $0.09.
Several other research firms have also commented on TARA. Lifesci Capital began coverage on Protara Therapeutics in a research report on Tuesday, March 11th. They set an "outperform" rating and a $22.00 price target for the company. Guggenheim reissued a "buy" rating and issued a $20.00 price objective on shares of Protara Therapeutics in a research report on Friday, December 6th. Finally, HC Wainwright restated a "buy" rating and set a $23.00 target price on shares of Protara Therapeutics in a research note on Thursday, March 6th. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Protara Therapeutics has a consensus rating of "Buy" and a consensus target price of $22.50.
Check Out Our Latest Stock Analysis on TARA
Protara Therapeutics Stock Performance
Shares of NASDAQ TARA traded up $0.01 during mid-day trading on Monday, reaching $4.54. 75,625 shares of the company's stock were exchanged, compared to its average volume of 788,909. The company's 50-day moving average is $4.27 and its 200-day moving average is $3.63. The firm has a market capitalization of $166.92 million, a price-to-earnings ratio of -1.61 and a beta of 1.69. Protara Therapeutics has a 52-week low of $1.60 and a 52-week high of $10.48.
Institutional Trading of Protara Therapeutics
A number of large investors have recently bought and sold shares of the business. XTX Topco Ltd acquired a new position in Protara Therapeutics in the third quarter valued at $60,000. HBK Investments L P acquired a new position in Protara Therapeutics in the 4th quarter valued at about $106,000. Squarepoint Ops LLC purchased a new stake in Protara Therapeutics during the 4th quarter valued at approximately $110,000. Dimensional Fund Advisors LP purchased a new stake in shares of Protara Therapeutics during the fourth quarter worth approximately $111,000. Finally, Bailard Inc. acquired a new stake in shares of Protara Therapeutics during the fourth quarter worth $157,000. Institutional investors and hedge funds own 38.13% of the company's stock.
Protara Therapeutics Company Profile
(
Get Free Report)
Protara Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in advancing transformative therapies for the treatment of cancer and rare diseases. The company's lead program is TARA-002, an investigational cell therapy, which is in Phase II clinical trial for the treatment of non-muscle invasive bladder cancer and lymphatic malformations.
See Also
Before you consider Protara Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Protara Therapeutics wasn't on the list.
While Protara Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
